# A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

> **NCT06524544** · PHASE3 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 320 (estimated)

## Conditions studied

- Locally Advanced Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Unresectable Urothelial Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Questionnaire Administration
- **BIOLOGICAL:** Sacituzumab Govitecan

## Key facts

- **NCT ID:** NCT06524544
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06524544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06524544, "A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT06524544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*